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Abstract
Objective. The role of the adaptive immune system has not been explored in detail compared with the
innate immune system in systemic JIA (sJIA) pathogenesis. The aim of this study was to examine the
phenotype of circulating peripheral blood CD4+ T-cell subpopulations in a cross-sectional study of sJIA
patients during disease remission on medication and during acute flare of the disease.
Methods. Flow cytometry was used to examine the phenotype and cytokine production of IFNg-, IL-4-
and IL-17-producing CD4+ T cells in the peripheral blood of 10 sJIA patients with active disease, 9 sJIA
with inactive disease, 14 JIA patients with oligoarticular onset, 10 adult control subjects and 10 age-
matched control subjects. In parallel, we examined the proportion of FoxP3+ Tregs.
Results. IFNg- and IL-17-producing CD4+ T cells and IL-17-producing CD3+CD4 T cells were present at
higher proportions in the peripheral blood of sJIA patients, irrespective of their disease status. Our data
also confirm the known increase of the proportions of IFNg-producing Th1 cells with increasing age and
suggest an increase with age in the IL-17-producing CD4+ T-cell population.
Conclusion. This study is the first to describe significantly higher proportions of Th1 and Th17 T helper
cell subsets in the peripheral blood of sJIA patients. These proinflammatory cells may play a pathogenic
role in sJIA. Our data also emphasize the importance of using paediatric age-matched control subjects
when evaluating the T-cell cytokine profile in JIA.
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Introduction
JIA is a clinically heterogeneous condition. There is strong
evidence that dysregulation in cytokines that mediate
innate immune responses plays a major role in the patho-
genesis of the systemic JIA subtype (sJIA). For example,
the cytokine IL-1 has an important role in sJIA. Pascual
et al. [1] reported spontaneous expression of IL-1b in peri-
pheral blood mononuclear cells (PBMCs) of sJIA patients
and also an IL-1 signature in gene expression studies. IL-6
production is markedly increased in the serum of sJIA
patients, and IL-6 levels have been shown to correlate
with disease activity, fever pattern and platelet count
[2, 3]. The weak association of HLA genes with sJIA as
compared with the strong HLA class II associations re-
ported in the other JIA subtypes [4], and the fact that
treatment of sJIA patients with biologic agents blocking
IL-1b and IL-6 signalling is highly effective in a substantial
proportion of patients resistant to conventional therapies
[1, 57], lend support to the view that the pathology of
sJIA is mainly within the innate immune system.
However, the cytokine milieu has a significant influence
on the polarization of naive T cells. For example, IL-1
and IL-6 are cytokines that differentiate T cells to IL-17-
secreting cells (Th17), which are implicated in autoim-
mune diseases [8, 9]. Moreover, in addition, Th17 T cells
can acquire a Th1 phenotype (Th17/1) and secrete IFNg
[10], contributing to the proinflammatory state.
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sJIA is a systemic disease, and increased circulating
cytokines have been detected during active disease
[13]. Therefore the proportions of different phenotypes
of T lymphocytes may be altered in the peripheral blood.
So far, few studies have examined circulating T cells in
children with sJIA. Moreover, the findings have been in-
consistent, with reports showing a decreased number of
Th2 cells or a mixed Th1/Th2 cytokine profile [11, 12]. In
this study we examined the phenotype of circulating per-
ipheral blood T-cell subpopulations in a cross-sectional
study of sJIA patients during disease remission on medi-
cation and during acute flare of the disease.
Materials and methods
Patients and samples
sJIA patients were divided into two groups: an inactive
disease group with no systemic features, no arthritis and
normal CRP/ESR, referred to as quiescent in this article.
The second group consisted of children with active dis-
ease; all have arthritis with or without systemic features
and raised CRP/ESR, referred to as flare or active in this
article (Table 1). For comparison, age-matched healthy
control subjects and oligoarticular onset JIA patients
were recruited. Peripheral blood samples of 10 sJIA pa-
tients with active disease, 9 with quiescent disease, 14 JIA
patients with oligoarticular JIA (9 with extended oligoar-
thritis and 5 with persistent oligoarthritis), 10 healthy adult
control subjects and 10 healthy age-matched control sub-
jects were included in this study. Data from seven of
the oligoarticular JIA patients cited in this study were
previously published data [13].
Clinical assessment at the time of sampling was per-
formed using the core set of variables for measurement of
JIA disease activity as defined by Giannini et al. [14]. All
patients attended the Great Ormond Street Hospital for
children in London. Ethics committee approval from
Great Ormond Street Hospital for Children NHS Trust
and Institute of Child Health Research Ethics Committee
and full written informed consent from the parents, adult
control subjects and parents of the age-matched control
subjects were obtained. PBMCs were isolated using
standard Ficoll-Hypaque density-gradient centrifugation
and cryopreserved until tested.
Analysis of cytokine production
For stimulation to analyse cytokine production, PBMCs
were cultured for 3 h in the presence of 50 ng/ml of
phobol myristate acetate, 500 ng/ml of ionomycin and
5mg/ml of Brefeldin A.
Standard five-colour flow cytometry was performed. For
surface markers, the following specific anti-human mAbs
were used: peridinin chlorophyll A protein or Qdot605-
conjugated CD4 (clones SK3, S3.5), fluorescein
isothiocyanate-conjugated anti-CD4 (clone Q4120),
phycoerythrin (PE)-Cy7 or peridinin chlorophyll A pro-
tein-Cy5.5-conjugated anti-CD3 (clones UCHT1, OKT3)
and PE-conjugated anti-CD25 (clone ACT-1).
For intracellular cytokine staining we used fluorescein
isothiocyanate or V500-conjugated IFNg (clone 25723.11,
B27), Alexa Fluor 647 or V450-conjugated IL-17 (clone
eBio64CAP17, N49-653) and PE-conjugated IL-4 (clone
3010.211). FoxP3 was detected in unstimulated cells
using allophycocyanin-conjugated anti-FoxP3 (clone
PCH101) antibody. Data were collected on a
FACSCalibur or LSRII flow cytometer (both from Becton
Dickinson and Co., Franklin Lakes, NJ, USA) and analysed
using FlowJo software (Tree Star, Ashland, OR, USA).
TABLE 1 Demographic and clinical characteristics of the sJIA patients at the time of sampling for this study
Patient demographics Flare (n=10) Quiescent (n=9)
Sex, M/F 4/6 6/3
Age years, median (range) 10 (417) 14 (1015)
Age at disease onset years, median (range) 5.5 (213) 5 (213)
Disease duration years, median (range) 3 (19) 9 (212)
CRP mg/l, median (range) 13.6 (486) <5 (<5<5)
ESR mm/h, median (range) 42 (295) 4 (<1<10)
Fever ± rash 6/10 0/9
Number of active joints, median (range) 5.5 (017) 0 (00)
Number of joints with a limitation of movement, median (range) 6 (017) 0 (00)
VAS of disease activity (physician’s), median (range), mm 36 (170) 0 (010)
VAS of overall well-being (parent’s), median (range), mm 33.5 (070) 1 (03)
Functional ability (CHAQ), median (range) 0.66 (02) 0.08 (00.13)
Pred 2/10 NR
Pred + MTX 6/10 NR
Pred + TOC 1/10 2/9
MTX + anakinra 1/10 NR
MTX + TOC NR 3/9
Pred + MTX + TOC NR 2/9
M/F: male/female; VAS: visual analogue scale; CHAQ: Childhood Health Assessment Questionnaire; Pred: prednisolone;
TOC: tocilizumab; NR: not reported.
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Statistical analysis
Data were analysed with GraphPad Prism software
(GraphPad Software, San Diego, CA, USA). Comparisons
between groups were made using MannWhitney U test.
P4 0.05 was considered significant.
Results
Enrichment of Th1 cells in the peripheral blood of sJIA
patients regardless of disease status
We examined the proportion of IFNg-producing CD4+
T cells in the peripheral blood of 10 systemic patients
with active disease and in 9 patients with quiescent dis-
ease. The disease activity measures, demographics and
medications taken at the time of sampling are shown in
Table 1. There was a significantly higher proportion of
IFNg-producing CD4+ T cells in PBMCs of all sJIA patients
regardless of the disease status [median 5.03%; inter-
quartile range (IQR) 3.78.99] as compared with PBMCs
of paediatric age-matched control subjects (median
2.65%; IQR 2.134.74; P= 0.0103) (Fig. 1A). The same
trend was observed in the two subgroups of systemic
patients with active and inactive disease when analysed
separately (P= 0.0147 and 0.0279, respectively).
To investigate whether the observed difference is
specific to the systemic subtype of JIA, we examined
14 patients with oligoarticular JIA. In PBMCs from oligoar-
ticular JIA patients, there was a trend for a higher median
number of IFNg-producing CD4+ T cells (4.62%; IQR
3.226.62) compared with age-matched control subjects
(2.65%; IQR 2.137.32), but this was not statistically
significant (Fig. 1A).
We also examined the proportion of IFNg-producing
and IL-4-producing cells among CD4+ T cells and the
CD3+CD4 T-cell population (which includes CD8 cells
and some gd T cells). These proportions did not differ sig-
nificantly between sJIA patients and paediatric age-
matched controls, even when disease status was taken
into consideration (data not shown).
Increased frequency of circulating IL-17-producing
CD4+ and CD3+CD4 T cells in sJIA
We investigated whether there was a difference in
the proportion of circulating Th17 cells in sJIA patients
as compared with healthy paediatric age-matched
controls. Children with sJIA showed a higher proportion
of IL-17-producing CD4+ T cells (median 0.64%; IQR
0.320.97) compared with the control group (median
0.32%; IQR 0.240.53), P= 0.0435 (Fig. 1B).
Interestingly, patients with inactive disease showed a sig-
nificantly higher proportion of Th17-producing CD4+
T cells (median 0.64%; IQR 0.470.86), P= 0.0101 than
the paediatric age-matched control subjects (Fig. 1B).
Likewise, the frequency of CD3+CD4 T cells producing
IL-17 was significantly different in sJIA patients compared
with control subjects (Fig. 1B), although the observed per-
centages were much smaller than that of CD4+ T cells. We
compared these results with the proportion of
IL-17-producing CD4+ T cells in the PBMCs of the other
14 patients with oligoarticular JIA, including data from
seven patients published in a previous study [13]. No
significant difference was observed (Fig. 1B).
Given that we have previously shown that in
proinflammatory environments, notably the synovial com-
partment of JIA, Th17 cells may convert into IFNg-produ-
cing cells, likely via a double-positive Th17/Th1
phenotype, we investigated the frequency of Th17/Th1
double-positive cells in the peripheral blood of sJIA pa-
tients. However, we found no significant difference in the
proportion of this double-positive population between
peripheral blood of sJIA patients (median 0.11%; IQR
0.00.14) and age-matched paediatric control subjects
(median 0.07%; IQR 0.050.10).
No difference in the proportion of FoxP3+ Tregs in
PBMCs of sJIA compared with adult or age-matched
paediatric control subjects.
We examined the number of circulating regulatory FoxP3+
CD4+ T cells in sJIA patients because of the increased
IL-17-producing CD4+ T cells. We have previously found
that FoxP3+ Tregs have a reciprocal relationship with
IL-17-producing T cells in the SF of JIA patients with
oligo- and polyarticular JIA [13], we tested whether this
was also the case in the peripheral blood of sJIA patients.
No significant difference was observed between the sJIA
patients and the paediatric and adult control groups, even
when stratifying according to disease activity (data not
shown).
Importance of using age-matched control subjects
in paediatric studies
We analysed PBMCs from both healthy adult and
age-matched paediatric control subjects for the propor-
tion of CD4+ cells secreting IFNg, IL-17 or IL-4 using flow
cytometry. Our data confirm an increase of the proportion
of IFNg-producing CD4+ T cells with increasing age [15];
being significantly higher in the adult control subjects
(median 12.09%; IQR 6.8318.90) as compared with the
healthy paediatric control subjects (median 2.65%; IQR
2.134.74), P= 0.0002 (Fig. 1A).
Our data also suggest that Th17 cells are present at
higher proportions within both the CD4+ and CD3+CD4
T-cell populations in healthy adults compared with healthy
children, P= 0.0001 and 0.0002, respectively (Fig. 1B). No
significant difference was observed when comparing
IL-4-producing CD4+ T cells (Th2) and FoxP3+ Tregs in
the age-matched control subjects and adult control sub-
jects (data not shown).
Discussion
In this study we have shown for the first time that both
IFNg-producing Th1 cells and IL-17-producing Th17 cells
are present in higher proportions in the peripheral blood of
sJIA patients compared with paediatric age-matched
controls, whereas no significant difference was observed
in the proportions of IL-4-producing Th2 cells or FoxP3+
Tregs.
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FIG. 1 Enrichment of Th1 cells and proportion of IL-17-producing CD4+ T cells and CD3+CD4 T cells in the peripheral
blood of sJIA patients.
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Previous studies of T-cell phenotypes in PBMCs of sJIA
have been inconsistent. Raziuddin et al. [12] showed
increased secretion of IL-4 and IL-10 with concomitant
deficiency of IL-2 and IFNg in the peripheral blood of
sJIA patients with active disease. However, Huang et al.
[11] reported a lower number of IL-4-producing Th2
cells, with no significant difference in IFNg-producing
Th1 cells.
The proinflammatory cytokines IL-1 and IL-6 have been
implicated in the pathogenesis of sJIA [13], with higher
plasma levels of IL-1 and IL-6 reported in sJIA patients
compared with paediatric age-matched control subjects
[16]. Because these cytokines are also involved in the de-
velopment of Th17 cells [8, 9], it is interesting that we
found an increased proportion of IL-17 in both CD4+
T cells and CD3+CD4 T cells in sJIA patients. Our results
also show that there is an increased proportion of
IFNg-producing cells in sJIA irrespective of clinical dis-
ease status when compared with paediatric age-matched
controls, unlike previous publications. These findings may
represent an underlying pathology that may lead to Th1
and Th17 cell populations persisting even when there are
no detectable markers of inflammation or symptoms. In
future, it would be interesting to compare the proportions
of Th1 and Th17 in patients early in their disease process
at presentation, a time when the pathology could reflect
triggering mechanisms leading to chronicity, and in
patients in remission off medication to see whether
these changes are specific markers of sJIA pathology.
Although we have previously published data showing
that the Th17 phenotype can evolve into IFNg-producing
T cells within a localized inflammatory environment [10],
we did not observe a significant difference in the double-
positive population between peripheral blood of sJIA pa-
tients and paediatric age-matched controls. In sJIA, the
mechanisms for the coexistence of increased proportions
of Th1 and Th17 cells in the peripheral blood may be dif-
ferent from previous findings in the SF. The observed
increased proportion of IL-17 irrespective of T-cell subpo-
pulation may be owing to the fact that all IL-17+ T cells,
including CD4+, CD8+ and CD4CD8 cells, originate
from CD161-expressing T-cell precursors, which upregu-
late IL-17 secretion in response to IL-1b and IL-23 [17].
Therefore, the enrichment of IL-17+ cells in both CD4+ and
CD4 T-cell subsets in sJIA suggests a common mech-
anism, possibly a result of dendritic cell/antigen present-
ing cell polarization towards IL-1b/IL-23 secretion.
An increasing role for Th17 cells has been found in
other diseases of innate immunity such as cryopyrin-
associated diseases [18, 19], with NLRP3 having an im-
portant role in Th17 responses [20]. Because sJIA is now
considered to have more in common with these autoin-
flammatory diseases, our finding is consistent with this
hypothesis. Therefore the interrelationships between
innate immunity mediators and effector T cell function
in sJIA merit further investigation. There may be a role
for adaptive immunity in a disease that is generally re-
garded as typically autoinflammatory, especially in the
case of sJIA.
Rheumatology key messages
. Both innate and adaptive immune mechanisms are
involved in the pathogenesis of sJIA.
. There is possible involvement of Th17 and Th1
effector T cells in the pathophysiology of sJIA.
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